Yardley, PA – September 12, 2022 - Red Nucleus (“RN”), a premier provider of strategic learning and development, scientic services and advisory, and medical communications solutions exclusively for the life sciences industry, announced that it has acquired Jupiter Life Science Consulting (“Jupiter”), a leading provider of commercial and market access strategies for global pharma, biotech, and medical device companies with its primary focus in rare disease, hematology/oncology, metabolic, and neurology therapeutic areas.
Jupiter, which was founded in 2015, helps clients achieve commercial success by providing unmatched expertise in global market access as well as complementary services in specialized commercial areas including portfolio optimization, commercial analysis, payer research, analytics, business development, and insights generation. Jupiter has evolved from decades of commercial and market access experience to deliver unparalleled expertise in the areas of shaping and communicating value, business development, pricing and access strategy, commercial planning, navigating payer behaviors, and general end-to-end commercial and market access support. Jupiter brings new clients and service offerings for the combined business.
Steve Slovick, Jupiter Managing Partner, adds “Our market access and commercialization expertise is a natural fit for the Red Nucleus brand. Their shared view on the importance of planning for and communicating product value to maximize success, along with their unique skill set and services, makes us excited for Jupiter’s long-term growth as part of the Red Nucleus family.”
"We are dedicated to maintaining continuity in our focus on quality, and we anticipate that the union with Red Nucleus will heighten the impact we create with our clients,” Jupiter Managing Partner Ted Sweeney adds.
“We are very pleased to welcome the Jupiter team to the Red Nucleus organization. At Red Nucleus, our mission is to be the global life sciences partner trusted to deliver transformative solutions across the product life cycle, and now with Jupiter, we can better do that with a fourth business unit focused on market access and commercialization excellence,” said Red Nucleus CEO Ian Kelly.
The transaction closed in September 2022.
See the press release on PR Web.
For more information, please contact
About Red Nucleus
Red Nucleus is the premier provider of strategic learning and development, scientific services and advisory, and medical communications solutions exclusively for the life sciences industry. For 30 years, we’ve taken pride in our long-term relationships with industry leaders, delivering global solutions designed to boost understanding, efficiency, and compliance. With worldwide offices in the United States, Japan, the United Kingdom, Sweden, India, Canada, Switzerland, Morocco, and Australia, our commitment to quality and on-time delivery is unrivaled in the industry.